RecruitingPhase 2Phase 3NCT06412666
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled and Open-Label Extension Trial to Evaluate the Efficacy and Safety of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Sponsor
Cytokinetics
Enrollment
55 participants
Start Date
May 29, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the efficacy, safety and PK of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Eligibility
Min Age: 12 YearsMax Age: 17 Years
Inclusion Criteria17
- Period 1: Treatment Period
- Males and females between 12 and \< 18 years of age at screening and at Day 1.
- Body weight ≥ 45 kg for the initial cohort and then body weight ≥ 35 kg after at least 10 participants in the initial cohort have undergone dose titration up to Week 4 without observed events of LVEF \< 50% at the starting dose of 5 mg qd.
- Core laboratory confirmation of the following oHCM echocardiographic criteria at screening:
- Left ventricular (LV) hypertrophy with nondilated LV chamber in the absence of other cardiac disease.
- LV end-diastolic wall thickness that meets a threshold of:
- Z-score \> 2.5 in the absence of family history OR
- Z-score \> 2 in the presence of positive family history or positive genetic test.
- LVEF ≥ 60% AND Valsalva LVOT-G ≥ 50 mmHg.
- oHCM of sarcomeric origin confirmed by genetic testing or, if unable to confirm by genetic testing, oHCM of sarcomeric origin may be presumed in the absence of history of metabolic disorders, mitochondrial cardiomyopathies, neuromuscular disease, malformation syndromes, infiltrative diseases/inflammation, and endocrine disorders (such as Fabry's disease, Noonan syndrome with left ventricular hypertrophy, and amyloid-cardiomyopathy).
- New York Heart Association (NYHA) Class ≥ II at screening.
- Adequate acoustic windows for echocardiography.
- Participants on beta blockers, verapamil, diltiazem, or disopyramide should have been on stable doses for more than 4 weeks prior to randomization.
- Period 2: Open-Label Extension
- Completed Period 1. If unable to complete Period 1 due to circumstances not related to compliance or safety, the Medical Monitor may review and determine eligibility.
- LVEF ≥ 55% after washout.
- Period 3: Long-term Extension • Completed Period 2.
Exclusion Criteria17
- Period 1: Treatment Period
- Any of the following criteria will exclude potential participants from the trial:
- Significant valvular heart disease.
- Moderate or severe valvular aortic stenosis or fixed subaortic obstruction.
- Mitral regurgitation that is greater than mild in severity and not due to systolic anterior motion of the mitral valve (per judgment of Principal Investigator or designee).
- Evidence of fixed left-sided obstruction (eg, subaortic membrane, aortic valve stenosis, or coarctation of the aorta).
- History of LV systolic dysfunction (LVEF \< 45%) or stress cardiomyopathy at any time during their clinical course.
- History of congenital heart disease other than oHCM (may be enrolled if not hemodynamically significant in the judgement of the Principal Investigator and study Medical Monitor).
- Has been treated with SRT (surgical myectomy or percutaneous alcohol septal ablation) within the preceding 6 months or has plans for either treatment during the trial period.
- History of paroxysmal or persistent atrial fibrillation or atrial flutter.
- History of syncope, symptomatic ventricular arrhythmia, or sustained ventricular tachyarrhythmia within 3 months prior to screening.
- History or evidence of any other clinically significant disorder, malignancy, active infection, other condition, or disease that, in the opinion of the Principal Investigator (or designee) or the Medical Monitor, would pose a risk to participant safety or interfere with the trial evaluation, procedures, or completion.
- Current or previous use of drugs known to cause cardiomyopathy (eg, anthracyclines, monoclonal antibodies \[trastuzumab\], alkylating agents \[cyclophosphamide\], and tyrosine kinase inhibitors \[sunitinib and imatinib\]).
- Currently participating in another investigational device or drug trial or received an investigational device or drug \< 1 month (or 5 half-lives for drugs, whichever is longer) prior to screening.
- Implantable cardioverter defibrillator (ICD) implantation within 6 weeks of screening or planned ICD implantation during the trial period.
- Has received prior treatment with aficamten or mavacamten.
- Currently listed for heart transplantation or anticipated to be listed for heart transplantation in the next 12 months.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGAficamten
Oral Tablet
DRUGPlacebo
Oral Tablet
Locations(38)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06412666
Related Trials
A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)
NCT0700497231 locations
Amputations in Childhood and Neuropathic Pain
NCT074019661 location
Quantifying Motor Network Dynamics to Predict and Enhance Outcomes in Pediatric Dystonia
NCT073251751 location
Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations
NCT032430192 locations
The Effectiveness of Dexmedetomidine as an Adjuvant for Bupivacaine Caudal Block in Pediatric Open Appendectomy Under General Anesthesia
NCT070889001 location